ASD

Bierman Autism Centers Unveils 'Adventures of Pilot the Penguin,' Educational Coloring Book, in Honor of Autism Acceptance Month

Retrieved on: 
Tuesday, April 2, 2024
LBA, Person-centered therapy, OTS, Penguin, Digital, BCBA, Physician, Bierman, Child, Aircraft pilot, Applied behavior analysis, Occupational therapy, LABA, Empowerment, OT, Creativity, Operation, ABA, Spectrum, ASD, Autism spectrum, Individual

This initiative highlights BAC's dedication to fostering understanding, igniting young imaginations, and actively engaging with families and communities about autism.

Key Points: 
  • This initiative highlights BAC's dedication to fostering understanding, igniting young imaginations, and actively engaging with families and communities about autism.
  • In celebration of Occupational Therapy Month, "Adventures of Pilot the Penguin" serves as a valuable resource for Occupational Therapists (OTs) at Bierman.
  • Our goal with this coloring book is to spark joy, foster educational discussions, and illuminate the incredible potential within children with autism."
  • “Adventures of Pilot the Penguin” represents more than just a coloring book; it embodies BAC's unwavering belief in the boundless potential of every child with autism.

White Gold Corp. Identifies Multiple Prospective IP Chargeability Anomalies on Two Large Multi-Element Porphyry Targets in Close Proximity to the Casino Copper-Gold Porphyry Deposit, Yukon, Canada

Retrieved on: 
Wednesday, March 27, 2024
Dawson Range, Lead, Copper, History, FRA, OTCQX, IP, RAB, Fracture, White Gold, Exploration, Silver, Anomaly, NW, Gold, Silver standard, Mitsubishi Materials, Bismuth, Propylitic alteration, WNW, M1, News, Textbook, Soil, Mining, Attention, Molybdenum, Zinc, 4N, Late Triassic, Tungsten, Late Cretaceous, ASD, Rare-earth element

All data collected thus far on these large early-stage targets continue to support a porphyry deposit model.

Key Points: 
  • All data collected thus far on these large early-stage targets continue to support a porphyry deposit model.
  • The new IP looked deeper than any previous geophysical surveys and demonstrates potential at depth beneath these large multi-element soil anomalies.
  • It’s now recommended to follow up with more IP survey lines to cover this large developing porphyry target.
  • The Bridget and Isaac targets represent large, early-stage, multi-element porphyry targets that have never been diamond drill tested.

Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office

Retrieved on: 
Wednesday, March 27, 2024
Research, Social anxiety, Composition, Brain, NCE, IPON, Environment, Patent, Incidence, Patient, University, Hyperthermia, Autism spectrum, MDXX, The central science, United States patent law, General Population (album), Test, IP, OTC, Spectrum, MDMA, Intellectual property, FDA, ASD, Food, Pharmaceutical industry

Preclinical testing has shown that the administration of ALA-002 results in significantly lowered incidence of hyperthermia, the major adverse event elicited by racemic generic MDMA.

Key Points: 
  • Preclinical testing has shown that the administration of ALA-002 results in significantly lowered incidence of hyperthermia, the major adverse event elicited by racemic generic MDMA.
  • PharmAla’s patent application included in-vivo experimental animal data, which is generally held to be stronger evidence than computational, or in-silico, modeling.
  • The Company intends to pursue its own clinical research with the novel composition, either alone or with an out-licensing partner.
  • “We are incredibly pleased that USPTO has issued an allowance for the granting of the Composition of Matter patent for ALA-002.

Bulat Utemuratov Foundation supports World Autism Awareness Day with initiatives across Kazakhstan

Retrieved on: 
Monday, April 8, 2024
Diagnosis, Health, Growth, Disease, Spectrum, Welfare, Quality of life, City, World Health Organization, Social skills, Social, Parent, ASD, Vaccine

ALMATY, Kazakhstan, April 8, 2024 /PRNewswire/ -- On 2 April, the Bulat Utemuratov Foundation marked World Autism Day by announcing it would be using the month to raise awareness of autism.

Key Points: 
  • ALMATY, Kazakhstan, April 8, 2024 /PRNewswire/ -- On 2 April, the Bulat Utemuratov Foundation marked World Autism Day by announcing it would be using the month to raise awareness of autism.
  • Over the month of April, the Foundation's Asyl Miras Autism Centers, which operate in 12 cities across Kazakhstan, will hold open days to educate visitors about ASD.
  • Marat Aitmagambetov, Director of the Bulat Utemuratov Foundation said, "In recent years we have seen an increase in parents requesting autism diagnostic consultations for their children.
  • Effective ASD management can significantly improve the social skills of children with the condition, and the Foundation remains committed to supporting Kazakhstanis with autism.

Bulat Utemuratov Foundation supports World Autism Awareness Day with initiatives across Kazakhstan

Retrieved on: 
Monday, April 8, 2024
Diagnosis, Health, Growth, Disease, Spectrum, Welfare, Quality of life, City, World Health Organization, Social skills, Social, Parent, ASD, Vaccine

ALMATY, Kazakhstan, April 8, 2024 /PRNewswire/ -- On 2 April, the Bulat Utemuratov Foundation marked World Autism Day by announcing it would be using the month to raise awareness of autism.

Key Points: 
  • ALMATY, Kazakhstan, April 8, 2024 /PRNewswire/ -- On 2 April, the Bulat Utemuratov Foundation marked World Autism Day by announcing it would be using the month to raise awareness of autism.
  • Over the month of April, the Foundation's Asyl Miras Autism Centers, which operate in 12 cities across Kazakhstan, will hold open days to educate visitors about ASD.
  • Marat Aitmagambetov, Director of the Bulat Utemuratov Foundation said, "In recent years we have seen an increase in parents requesting autism diagnostic consultations for their children.
  • Effective ASD management can significantly improve the social skills of children with the condition, and the Foundation remains committed to supporting Kazakhstanis with autism.

Hopebridge Gears Up for World Autism Month, Spreads Awareness of 1 in 36 Autism Prevalence

Retrieved on: 
Monday, March 25, 2024
Element, Speech, Social, Prevalence, Learning, Communication, Education, Research, Autism spectrum, Social media, Behavior, CDC, Spectrum, ASD, Residential care

Hopebridge Autism Therapy Centers, one of the largest autism therapy providers in the nation, is preparing for an exciting month ahead: World Autism Month.

Key Points: 
  • Hopebridge Autism Therapy Centers, one of the largest autism therapy providers in the nation, is preparing for an exciting month ahead: World Autism Month.
  • Hopebridge emphasizes to the public that this is a time to recognize and raise awareness about autism spectrum disorder (ASD) acceptance and inclusion.
  • To Hopebridge, the month of April is an opportunity to ignite change for children, families and the autism community as a whole.
  • "World Autism Month is a time to celebrate the diversity and resilience of individuals on the autism spectrum,” said Hopebridge founder, Kim Strunk.

Rose Hill Partners with University of Guelph for Groundbreaking Study to Advance Research for the Potential Benefits of Psilocybin Mushrooms to Address Autism in the Adolescent Brain

Retrieved on: 
Thursday, March 21, 2024
Psilocybin, University of Guelph, Research, Certification, Brain, Learning, University, Memory, Associate, Partnership, Patient, Knowledge, Fungus, Agriculture, Anxiety, Adolescence, Autism spectrum, Biomedical sciences, Spectrum, ASD, Biomass, Pharmaceutical industry

This collaboration marks a significant milestone for both entities as they embark on a pioneering exploration of the potential benefits of psilocybin to address autism in the adolescent brain, the first-of-its-kind partnership in this space.

Key Points: 
  • This collaboration marks a significant milestone for both entities as they embark on a pioneering exploration of the potential benefits of psilocybin to address autism in the adolescent brain, the first-of-its-kind partnership in this space.
  • The collaborative preclinical research will focus on exploring and standardizing the chemical diversity of Rose Hill’s psilocybin mushrooms, legally imported from Jamaica to Canada for the work.
  • Additionally, utilizing a rodent model, the study will investigate their potential application in Autism Spectrum Disorders (ASD).
  • Psilocybin mushrooms, known for their psychoactive properties, have long captivated the scientific community's interest due to their potential therapeutic applications and unique biochemical composition.

SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial

Retrieved on: 
Thursday, March 14, 2024
Central nervous system, Patient, Hope, Soroka Medical Center, Clinical trial, Safety, Disorder, TEL, Deviance (sociology), ASD, Autism spectrum, Pharmaceutical industry

TEL AVIV, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced that it has successfully dosed the first patient in its SCI-210 clinical trial at the Soroka Medical Center for pediatric patients who have Autism Spectrum Disorder ("ASD"). This significant milestone follows the Company's recent announcement about the successful delivery of its innovative SCI-210 treatment to the clinical trial site, enabling the commencement of dosing.

Key Points: 
  • This significant milestone follows the Company's recent announcement about the successful delivery of its innovative SCI-210 treatment to the clinical trial site, enabling the commencement of dosing.
  • "Dosing the first patient is always an exciting moment in any clinical trial.
  • We are grateful to the patients, Professor Meiri and his team involved in the clinical trial.
  • Designed as a randomized, double-blind, placebo-controlled clinical trial with cross-over, the study will span 20 weeks and enroll 60 children.

PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments

Retrieved on: 
Wednesday, March 13, 2024
Therapy, ASD, Public, Hope, IBN, Communication, DSM-IV codes, Pharmaceutical industry

TARRYTOWN, New York, March 13, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica , Inc. (NASDAQ: PXMD ), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the release of its latest company presentation .

Key Points: 
  • TARRYTOWN, New York, March 13, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica , Inc. (NASDAQ: PXMD ), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the release of its latest company presentation .
  • The new presentation, available on the PaxMedica website, outlines the company’s focused pipeline, including its leading investigational drug, PAX-101.
  • "PaxMedica is pleased to share our vision and progress with the wider community," said Howard Weisman, Chairman and CEO of PaxMedica.
  • For more information about PaxMedica and to access the presentation, please visit https://investorbrandnetwork.info/pxmd/id/index.html

Report Finds Indigenous-Led Housing Essential to Addressing Increased Risk of Homelessness for Indigenous Peoples with Diverse Abilities

Retrieved on: 
Tuesday, March 12, 2024
Research, Diagnosis, Health, Homelessness, Organization, FASD, Indigenous peoples, Assistant, Anonymous, Partnership, Risk, Education, Mental health, Policy, Disability studies, Child, Outline of health sciences, Housing, Musqueam Indian Band, Literature, AHMA, Simon Fraser University, ASD, Nursing

The report makes 26 recommendations and highlights the critical importance of promoting and funding Indigenous-led housing options as a path to creating more equitable, culturally supportive housing options for Indigenous Peoples with diverse abilities.

Key Points: 
  • The report makes 26 recommendations and highlights the critical importance of promoting and funding Indigenous-led housing options as a path to creating more equitable, culturally supportive housing options for Indigenous Peoples with diverse abilities.
  • Evidence based findings reveal numerous barriers Indigenous people with diverse abilities face in accessing housing, especially for those who also have complex and concurrent mental health and substance use care needs.
  • These are the most vulnerable populations, and a lack of housing support in a complex web of systems and services increases the risk of falling into a cycle of homelessness.
  • AHMA is a For Indigenous, By Indigenous organization made up of 55 members that represent over 95% of Indigenous housing and service providers in BC.